JP7191927B2 - 育毛促進及び脱毛または過剰な毛髪脱落の治療 - Google Patents

育毛促進及び脱毛または過剰な毛髪脱落の治療 Download PDF

Info

Publication number
JP7191927B2
JP7191927B2 JP2020501509A JP2020501509A JP7191927B2 JP 7191927 B2 JP7191927 B2 JP 7191927B2 JP 2020501509 A JP2020501509 A JP 2020501509A JP 2020501509 A JP2020501509 A JP 2020501509A JP 7191927 B2 JP7191927 B2 JP 7191927B2
Authority
JP
Japan
Prior art keywords
minoxidil
hair
range
hair loss
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020501509A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020527146A5 (cg-RX-API-DMAC7.html
JP2020527146A (ja
Inventor
シンクレア，ロドニー
Original Assignee
サムソン クリニカル プロプライエタリー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017902722A external-priority patent/AU2017902722A0/en
Application filed by サムソン クリニカル プロプライエタリー リミテッド filed Critical サムソン クリニカル プロプライエタリー リミテッド
Publication of JP2020527146A publication Critical patent/JP2020527146A/ja
Publication of JP2020527146A5 publication Critical patent/JP2020527146A5/ja
Priority to JP2022195386A priority Critical patent/JP2023016964A/ja
Application granted granted Critical
Publication of JP7191927B2 publication Critical patent/JP7191927B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
JP2020501509A 2017-07-12 2018-07-12 育毛促進及び脱毛または過剰な毛髪脱落の治療 Active JP7191927B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022195386A JP2023016964A (ja) 2017-07-12 2022-12-07 育毛促進及び脱毛または過剰な毛髪脱落の治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2017902722A AU2017902722A0 (en) 2017-07-12 Promoting hair growth and treatment of hair loss or excessive hair shedding
AU2017902722 2017-07-12
PCT/AU2018/050719 WO2019010535A1 (en) 2017-07-12 2018-07-12 STIMULATION OF HAIR GROWTH AND TREATMENT OF HAIR FALL OR EXCESSIVE ALOPECIA

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022195386A Division JP2023016964A (ja) 2017-07-12 2022-12-07 育毛促進及び脱毛または過剰な毛髪脱落の治療

Publications (3)

Publication Number Publication Date
JP2020527146A JP2020527146A (ja) 2020-09-03
JP2020527146A5 JP2020527146A5 (cg-RX-API-DMAC7.html) 2021-08-19
JP7191927B2 true JP7191927B2 (ja) 2022-12-19

Family

ID=65001077

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020501509A Active JP7191927B2 (ja) 2017-07-12 2018-07-12 育毛促進及び脱毛または過剰な毛髪脱落の治療
JP2022195386A Withdrawn JP2023016964A (ja) 2017-07-12 2022-12-07 育毛促進及び脱毛または過剰な毛髪脱落の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022195386A Withdrawn JP2023016964A (ja) 2017-07-12 2022-12-07 育毛促進及び脱毛または過剰な毛髪脱落の治療

Country Status (10)

Country Link
US (2) US20190269684A1 (cg-RX-API-DMAC7.html)
EP (1) EP3651769B1 (cg-RX-API-DMAC7.html)
JP (2) JP7191927B2 (cg-RX-API-DMAC7.html)
KR (2) KR20240064747A (cg-RX-API-DMAC7.html)
CN (1) CN111065396A (cg-RX-API-DMAC7.html)
AU (2) AU2018250398B2 (cg-RX-API-DMAC7.html)
CA (1) CA3069336A1 (cg-RX-API-DMAC7.html)
ES (1) ES2909395T3 (cg-RX-API-DMAC7.html)
SG (1) SG11202000124PA (cg-RX-API-DMAC7.html)
WO (1) WO2019010535A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ732075A (en) 2014-10-29 2022-09-30 Samson Clinical Pty Ltd Detection and treatment of excessive hair shedding
GB2596942B (en) 2019-02-27 2023-05-10 Samson Clinical Pty Ltd Tofacitinib via oral mucosa for use in treatment of autoimmune hair loss or excessing hair shedding
WO2021178871A1 (en) 2020-03-05 2021-09-10 University Of Miami Cannabidiol nanodrug formulations and methods for use the same
CN112691187B (zh) * 2020-12-30 2021-12-21 深圳新发源植物科技发展有限公司 一种用于防止额前脱发的缓释膜及其制备方法
CN113248501B (zh) * 2021-06-17 2021-10-08 南京韦尔优众医药有限公司 Cly系列化合物及其制备方法和制备药物的用途
KR20250100660A (ko) 2022-10-25 2025-07-03 베라더믹스 인코포레이티드 변형 방출 미녹시딜의 조성물 및 사용 방법
EP4539816A4 (en) * 2023-09-01 2025-07-23 Follea Int COMPOSITIONS AND METHODS FOR AN ORALLY ADMINISTERED MINOXIDIL SUPPLEMENT FOR THE TREATMENT OF ALOPECIA
KR20260065905A (ko) * 2023-09-08 2026-05-11 수조우 킨터 제약회사(주) 안드로겐 수용체 억제제/길항제를 함유하는 약학 조성물, 방법 및 용도
GB2638418A (en) * 2024-02-21 2025-08-27 Novumgen Ltd An orodispersible tablet of spironolactone and its process of preparation
WO2026062695A1 (en) * 2024-09-17 2026-03-26 Shah Atul K Toothpaste for body disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009091325A (ja) 2007-10-11 2009-04-30 Rohto Pharmaceut Co Ltd 育毛剤
JP2012504135A (ja) 2008-09-27 2012-02-16 ジャイナ ファーマシューティカルズ，インコーポレーテッド 経口適用および局所適用のための脂質系薬学的調製物、ならびにそれらの組成物、方法、および使用
WO2016065426A1 (en) 2014-10-29 2016-05-06 Samson Clinical Pty Ltd Detection and treatment of excessive hair shedding

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997643A (en) * 1989-07-12 1991-03-05 Union Carbide Chemicals And Plastics Company Inc. Polymeric salt delivery systems
GB2314019B (en) * 1996-06-10 2000-03-15 Bio Scient Ltd The use of L-Lysine in the treatment of hair loss
WO1999040898A2 (en) * 1998-02-12 1999-08-19 Centrapharm Inc. Sublingual drug formulations having combined rapid onset of action and long lasting therapeutic effect
US20050271596A1 (en) * 2002-10-25 2005-12-08 Foamix Ltd. Vasoactive kit and composition and uses thereof
CN1838969A (zh) * 2004-10-07 2006-09-27 三仪股份有限公司 经皮和经粘膜制剂
EP2510930A1 (en) * 2011-04-15 2012-10-17 Bionanoplus, S.L. Nanoparticles comprising half esters of poly (methyl vinyl ether-co-maleic anhydride) and uses thereof
AU2011100917B4 (en) * 2011-07-26 2013-05-02 Sinclair, Rodney Daniel Professor Treatment of male and female androgenetic alopecia with oral minoxidil either alone or in combination with antiandrogens
WO2013181487A2 (en) * 2012-05-31 2013-12-05 Stiefel Laboratories, Inc. Method of treating
US9561224B1 (en) * 2015-05-27 2017-02-07 Moshe Rogosnitzky Methods and compositions for treating androgenetic alopecia

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009091325A (ja) 2007-10-11 2009-04-30 Rohto Pharmaceut Co Ltd 育毛剤
JP2012504135A (ja) 2008-09-27 2012-02-16 ジャイナ ファーマシューティカルズ，インコーポレーテッド 経口適用および局所適用のための脂質系薬学的調製物、ならびにそれらの組成物、方法、および使用
WO2016065426A1 (en) 2014-10-29 2016-05-06 Samson Clinical Pty Ltd Detection and treatment of excessive hair shedding

Also Published As

Publication number Publication date
AU2018250398B2 (en) 2019-02-28
WO2019010535A1 (en) 2019-01-17
AU2019203438A1 (en) 2019-06-06
AU2018250398A1 (en) 2019-01-31
CN111065396A (zh) 2020-04-24
ES2909395T3 (es) 2022-05-06
KR20240064747A (ko) 2024-05-13
JP2023016964A (ja) 2023-02-02
CA3069336A1 (en) 2019-01-17
SG11202000124PA (en) 2020-02-27
US20190269684A1 (en) 2019-09-05
EP3651769A1 (en) 2020-05-20
EP3651769B1 (en) 2022-01-05
US20250064807A1 (en) 2025-02-27
KR102663164B1 (ko) 2024-05-07
NZ760579A (en) 2024-09-27
EP3651769A4 (en) 2021-04-21
JP2020527146A (ja) 2020-09-03
BR112020000508A2 (pt) 2020-07-14
KR20200028403A (ko) 2020-03-16

Similar Documents

Publication Publication Date Title
JP2023016964A (ja) 育毛促進及び脱毛または過剰な毛髪脱落の治療
JP5758812B2 (ja) ステロイド組成物
US7919115B2 (en) Orally disintegrating tablet compositions of lamotrigine
JP4920798B2 (ja) ２種以上の粒子を含有する口腔内速崩壊錠
AU2017203009B2 (en) Diethylstilbestrol dosage form and use for the treatment of prostate or breast cancer
US20250381192A1 (en) Treatment of Autoimmune Disease
CN1913876B (zh) 含药物的颗粒和包含这种颗粒的固体制剂
JP7091477B2 (ja) エダラボン医薬組成物
JP5122984B2 (ja) 改良された薬物動態学的特性を有する製剤
EA034288B1 (ru) Система доставки лекарственного средства
AU2022200479A1 (en) Treatment of autoimmune disease
WO2021171318A1 (en) Transmucosal pharmaceutical composition of levocetirizine
WO2014035355A1 (en) Pharmaceutical combination comprising idebenone and memantine
ES3060119T3 (en) Pharmaceutical composition comprising eliglustat
JP6061924B2 (ja) 口腔内分散性製剤
HK40018518A (en) Promoting hair growth and treatment of hair loss or excessive hair shedding
HK40018518B (en) Promoting hair growth and treatment of hair loss or excessive hair shedding
BR122025006573A2 (pt) Composição dispersível
BR112020000508B1 (pt) Composição orodispersível e uso de uma composição orodispersível
EP2962685B1 (en) Orally disintegrating formulations of tadalafil
JP2009504568A (ja) 女性型脱毛症等の毛髪成長障害の治療方法とそのために有用な組成物
Maroni et al. Pharmaceutical formulations of nimesulide

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210707

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210707

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220524

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220819

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221108

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221207

R150 Certificate of patent or registration of utility model

Ref document number: 7191927

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250